3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
28
Neoplasms
15
Carcinoma, Non-Small-Cell Lung
7
Multiple Myeloma
6
Hematologic Neoplasms
6
Neoplasm Metastasis
4
Lymphoma
4
Leukemia, Myeloid, Acute
3
Colorectal Neoplasms
3
Brain Neoplasms
3
Biliary Tract Neoplasms
3
Thyroid Neoplasms
2
Thyroid Cancer, Papillary
2
Skin Neoplasms
2
Glioma
2
Cholangiocarcinoma
2
Bile Duct Neoplasms
2
Adenocarcinoma, Follicular
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oligodendroglioma
1
Nonseminomatous germ cell tumor
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurocytoma
1
Neuroblastoma
1
Myelodysplastic Syndromes
1
Interventions
Nivolumab
4
pembrolizumab
3
pertuzumab
2
durvalumab
2
Paclitaxel
2
Docetaxel
2
Capecitabine
2
ulocuplumab
1
tremelimumab
1
tazarotene
1
talazoparib
1
romiplostim
1
pexidartinib
1
pamiparib
1
onartuzumab
1
magrolimab
1
entrectinib
1
cobimetinib
1
atezolizumab
1
Sunitinib
1
Rifampin
1
Ramucirumab
1
Radiosurgery
1
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
1
Midazolam
1
MK-4166
1
LY3022855
1
LY2510924
1
LY-2157299
1
Itraconazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Solid Tumor
×
trametinib
×
Clear all
No trials found.